Argenica Therapeutics (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.
The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.
Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.
Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.
Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。